Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC
Introduction - Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). - Methods - In this multicenter, open-label phase 1a/b trial, patients received ramucirumab 10 mg/kg and pembrolizumab 200 mg every 21...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2021
|
| In: |
Journal of thoracic oncology
Year: 2021, Volume: 16, Issue: 2, Pages: 289-298 |
| ISSN: | 1556-1380 |
| DOI: | 10.1016/j.jtho.2020.10.004 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2020.10.004 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086420308091 
|
| Author Notes: | Roy S. Herbst, MD, PhD, Hendrik Tobias Arkenau, MD, Johanna Bendell, MD, Edward Arrowsmith, MD, Martin Wermke, MD, Andres Soriano, MD, Nicolas Penel, MD, Rafael Santana-Davila, MD, Helge Bischoff, MD, Ian Chau, MD, Gu Mi, PhD, Hong Wang, PhD, Erik Rasmussen, PhD, David Ferry, MD, Bo H. Chao, MD, Luis Paz-Ares, MD |